Search, analyze & compare
My selected companies
Adjust valuation method
![]()
Detail of HilleVax, Inc.
CEO
Dr. Robert M. Hershberg M.D., Ph.D.
Employees
90
Industry
Biotechnology
Sector
Healthcare
Market cap
$91M
Company details
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
Stock vs Industry average
-
Industry average
Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$3.04
Margin profit
0.00%
52 week low
$1.58
52 week high
$19.75
50-day simple moving average
$0.00
200-day simple moving average
$2.11
Percent held by insiders
17.11%
Percent held by institutions
91.57%
Dividend yield
0.00%
